Vol. 5 No. 10 (2025)
Reimbursement Recommendations

Pertuzumab

decorative image of the issue cover

Published October 3, 2025

Key Messages

  • The Formulary Management Expert Committee (FMEC) recommends that pertuzumab in combination with trastuzumab and chemotherapy be reimbursed for the treatment of adults with early-stage HER2-positive breast cancer in the neoadjuvant setting, provided certain conditions are met.
  • Pertuzumab in combination with trastuzumab and chemotherapy may be initiated in adult patients for the neoadjuvant treatment of early-stage HER2-positive breast cancer if all of the following conditions are met: it is locally advanced, inflammatory or early-stage breast cancer (> 2 cm or node positive) and there is no evidence of metastasis. A price reduction for pertuzumab may be required.